

Ref. No.: WOCK/SEC/SE/2024-25/037

09th August, 2024

BSE Limited	National Stock Exchange of India Limited		
Corporate Relations Department	Exchange Plaza		
P J Towers	Bandra Kurla Complex		
Dalal Street	Bandra (E)		
Mumbai - 400 001	Mumbai - 400 051		
Scrip Code: 532300	NSE Symbol: WOCKPHARMA		

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2024.

A copy of the same will also be uploaded on the Company's website www.wockhardt.com

Kindly take the same on record please.

Thanking you, For **Wockhardt Limited**

Rashmi Mamtura Company Secretary

Encls: A/a




Mumbai, August 9th, 2024:

3 Fold Growth in Wockhardt's EBITDA at Rs.100 crore

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1st Quarter Results for Financial Year 2024-25, today.

- YoY growth of 14% in revenue in Q1FY25, Revenue for Q1FY25 of INR 747 Cr compared to INR 658 Cr in the previous year.
- YoY growth of 216% in EBITDA in Q1FY25, EBITDA for Q1FY25 at INR 100 Cr compared to INR 32 Cr in the previous year.



Novel Antibiotic Update:

ZAYNICH (WCK 5222): We continue to recruit more patients for our global clinical trial and have recruited 422 patients. Clinical Trial study progressing in 9 countries. We have completed 33 patients for compassionate use after approval of usage by DCGI. The product resulted in 100% cure and was found to be safe even when administered upto 60 days.



Meropenem Resistance Clinical Trial: DCGI has advised to do a Clinical Trial of 60 patients study. 25% patients have been recruited. This Clinical Trial would be completed within the next 8 to 9 months post which WCK 5222 (ZAYNICH) can be launched in India by early 2025.

Meropenem Resistance Clinical Trial 60 Patients Study Completion in 8-9 Months

Globally renowned US body Clinical and laboratory Standards Institute (CLSI) has awarded high susceptibility breakpoints to Zaynich. In June 2024 plenary session of CLSI Zaynich has been granted a susceptibility breakpoint of 64 mg/L for around 10 Gram negative pathogens showing high resistance rates. Susceptibility breakpoints

CLSI	Awards			
64 mg/L	HIGH SUSCEPTIBILITY			
ZAYNICH	BREAKPOINTS			



guides the doctors about selection of most efficacious antibiotic for treating various infections caused by different pathogens. A high breakpoint of 64 mg/L suggests Zaynich's strong potential to cover all the clinically important, extreme drug resistant Gram negative pathogens in seriously ill patients.

ZAYNICH successfully treats US PATIENT with EXTREME DRUG-RESISTANT PSEUDOMONAS INFECTION Zaynich has also been used successfully to treat a cancer patient in US with Chronic Bilateral Thigh Infection caused by an Extreme-Drug Resistant Pseudomonas. This case marks the first instance in the US where Zaynich has been employed to combat a complex infection caused by extreme-drug resistant Pseudomonas.

MIQNAF (WCK 4873): The Company has announced the completion of the pivotal Phase 3 pneumonia study of its antibiotic Nafithromycin WCK 4873 (MIQNAF). The product has been filed for DCGI approval which is expected in the Q3FY25. Commercial launch expected in Q4FY25.

After 30 years, a new oral antibiotic MIQNAF (WCK 4873) will be shortly introduced in India and it is for Community Acquired Pneumonia with a success rate of over 97%. This will meet a major antibiotic community need as existing drugs like Azithromycin has high resistance of 60%. It is only a three-day treatment and it has eight times higher lung concentration than Azithromycin.




Business Highlights (Q1FY25):

- **UK Business** stood at Rs.276 crore in Q1FY25 compared to Rs.247 crore in Q1FY24 registering a growth of 12% and contributed about 37% of Global Revenue in the current quarter.
- Emerging Markets Business of the Company stood at Rs.191 crore in Q1FY25 registering a growth of 44% and contributing to about 26% of the Global Revenue.
- Irish Business stood at Rs.45 crore in Q1FY25 with a flat growth compared to the previous year.
- India Branded Business stood at Rs.123 crore in Q1FY25 compared to Rs.100 crore in the previous year registering a growth of 23% and contributing to 16% of the Global Revenue.
- US Business stood at Rs.30 crore in Q1FY25 contributing 4% of the Global Revenue.



New Products Launch:

- □ 2 Filings and 6 launches in Q1FY25 in UK
- **2** New launches in Ireland
- Registration has been filed in 10 countries of ROW for EMROK and EMROK O



Intellectual Property Update:

- 2 patents were filed during the quarter ended 30th June, 2024 and the cumulative filings till date are 3265.
- □ The company was granted 2 patents during the quarter and now holds 842 patents.

PATENTS						
Filings till Date	:	3265				
Patents Granted	:	842				

Financial Highlights:

	Q1 FY25	Q1 FY24	Q4 FY24
Particulars	Apr - Jun	Apr - Jun	Jan - Mar
	2024	2023	2024
Total Revenue	747	658	750
EBITDA before R&D	127	67	103
EBITDA % to Sales	16.9%	10.2%	13.8%
R&D	27	36	33
R&D % to Sales	3.6%	5.4%	4.4%
EBITDA	100	32	70
EBITDA Margins %	13.4%	4.8%	9.4%
Exceptional Items	-	(14)	-
Impairment of asset held for sale & loss on sale of property, plant & equipment #	-	-	(123)
РВТ	(6)	(118)	(180)
Profit After Tax	(16)	(136)	(177)
PAT Margins %	-2.1%	-20.7%	-23.6%

In Q4FY24 the company had recognized an impairment loss of Rs. 79 crore on assets held for sale. Additionally, the company had incurred a loss of Rs. 42 crore on the sale of property, plant, and equipment attributable to the restructuring of the company's US operations.



About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where

DRUG DISCOVERY PROGRAMME USFDA QIDP STATUS : 6 ANTI-BACTERIALS

USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing around ~2600 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 78% of its global revenues coming from international businesses.